3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
1
Interventions
Gemcitabine
4
Cisplatin
2
vinflunine
1
valrubicin
1
pembrolizumab
1
enfortumab vedotin
1
cabazitaxel
1
XRP6258
1
Rogaratinib
1
Oncolytic Virotherapy
1
Mitomycin
1
Interferons
1
Drug Therapy
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Transitional Cell
×
Rogaratinib
×
Clear all
NCT03410693
2022-09-28
FORT-1
Bayer
Phase 2/3
Completed
175 enrolled
19 charts